Fresenius acquires remaining 45% of mAbxience, taking full ownership of its biosimilars platform

Building on a successful partnership since 2022, Fresenius has completed the acquisition of mAbxience. Together, the companies will strengthen development, manufacturing and commercial capabilities to help expand access to high-quality biosimilars for patients worldwide.